Jump to main content
Jump to site search

Issue 12, 2016
Previous Article Next Article

In vivo SAR and STR analyses of alkaloids from Picrasma quassioides identify 1-hydroxymethyl-8-hydroxy-β-carboline as a novel natural angiogenesis inhibitor

Author affiliations

Abstract

Angiogenesis plays an important role in the development of inflammatory diseases, including cancer, psoriasis and rheumatoid arthritis. In this paper, we conducted a zebrafish bioassay-guided fractionation of Picrasma quassioides and identified twenty alkaloids from the anti-angiogenic fraction, including four new ones (1–4). In addition, in vivo relationship analyses of the structure and anti-angiogenic activity/toxicity led to the conclusion that the skeleton of alkaloids as well as the positions and properties of the substituents are pivotal to their activity and toxicity. Furancanthin (1) is the first-reported furan-fused canthin-6-one with an unprecedented highly-conjugated pentacyclic skeleton. 1-Hydroxymethyl-8-hydroxy-β-carboline (3) was found to have the most potent anti-angiogenic activity and the lowest toxicity in vivo, whose anti-angiogenic activity was also confirmed in vitro. Further qRT-PCR analysis revealed that the kdr, kdrl signaling axle in the VEGF–VEGFR pathway and the angpt2b, tek in the ANGPT–TEK pathway seemed to be involved in the anti-angiogenic activity of compound 3.

Graphical abstract: In vivo SAR and STR analyses of alkaloids from Picrasma quassioides identify 1-hydroxymethyl-8-hydroxy-β-carboline as a novel natural angiogenesis inhibitor

Back to tab navigation

Supplementary files

Publication details

The article was received on 26 Oct 2015, accepted on 10 Jan 2016 and first published on 14 Jan 2016


Article type: Paper
DOI: 10.1039/C5RA22391A
Author version
available:
Download author version (PDF)
Citation: RSC Adv., 2016,6, 9484-9494
  •   Request permissions

    In vivo SAR and STR analyses of alkaloids from Picrasma quassioides identify 1-hydroxymethyl-8-hydroxy-β-carboline as a novel natural angiogenesis inhibitor

    G. Gong, Q. Lin, J. Xu, F. Ye, L. Jiang, W. Liu, M. He, F. Feng, W. Qu and N. Xie, RSC Adv., 2016, 6, 9484
    DOI: 10.1039/C5RA22391A

Search articles by author

Spotlight

Advertisements